Stablepharma highlighted in European Pharmaceutical Review

Stablepharma highlighted in European Pharmaceutical Review as one of the innovative SMEs who are working to combat the current pandemic and improve the UK’s vaccine capabilities in preparation for future outbreaks. 

See an excerpt from the article below:

In 2018, the UK Government Industrial Strategy Challenge Fund (ISCF) invested £66m in the creation of the Vaccines Manufacturing Innovation Centre (VMIC), which is currently being built in Oxfordshire. The centre is also backed up by private investment from Janssen Vaccines & Prevention and MSD, as well as expertise and training from Cytiva.4 In response to COVID-19, the UK Government has invested a further £131m to accelerate the completion of the centre and create a temporary manufacturing facility (“Virtual VMIC”) ready to make vaccines at pace and scale to support the manufacturing of a COVID-19 vaccine when it is ready.

Another COVID-19 initiative launched by the Government was the creation of a Vaccine Taskforce to rapidly manage the development and deployment of the vaccine. It has selected the two candidates described above. Both of these vaccines are now being tested in humans and the Taskforce has co-ordinated public and private sector organisations involved in their development and used the UK’s R&D expertise to support international vaccine efforts.

If everything goes according to plan, the Oxford/ AstraZeneca vaccine could be approved for human use later this year and subsequently made available for vaccinations in the UK and worldwide through agreements with organisations including CEPI, Gavi and the Serum Institute of India. The Imperial College London vaccine is expected to be ready for UK administration in early 2021.

The vaccine innovation landscape in the UK has a rich diversity of university laboratories, research institutes and innovative companies working on prophylactic vaccines. The full article lists some of the UK SME innovators in this space and several will be highlighted below.

Read the full article here.